Market Place
Sourcing Support
All News #Library
Rare Diseases
FDA Approves Regeneron`s First Gene Therapy for Hearing Loss
24 Apr 2026 //
FDA
Dupixent Approval For Children With Chronic Spontaneous Urticaria
22 Apr 2026 //
PRESS RELEASE
FDA Grants Priority Review to Garetosmab for FOP
19 Feb 2026 //
GLOBENEWSWIRE
FDA Approves Eylea HD 8 mg for RVO Macular Edema
19 Nov 2025 //
GLOBENEWSWIRE
Regeneron, AZ Regulatory Plans Bolstered By Ph. 3 Wins
07 Nov 2025 //
BUSINESSWIRE
Evkeeza Approval For Ultra-Rare Pediatric High Cholesterol
26 Sep 2025 //
GLOBENEWSWIRE
Regeneron Donates Ebola Treatment to High-Risk Countries
19 Sep 2025 //
GLOBENEWSWIRE
Regeneron`s Rare Bone Disorder Drug Succeeds in Late-Stage Trial
17 Sep 2025 //
REUTERS
Targeted Myasthenia Gravis Therapies Flood Sparse Market
15 Sep 2025 //
BIOSPACE
Regeneron`s Immune Disorder Therapy Improves Functions in Trial
27 Aug 2025 //
REUTERS
Regeneron Reports Ph3 Success in Generalized Myasthenia Gravis
26 Aug 2025 //
GLOBENEWSWIRE
Regeneron Science Talent Search 2025 Awards Over $1.8 Million
11 Mar 2025 //
GLOBENEWSWIRE
Regeneron gene therapy improves hearing in 10 children
25 Feb 2025 //
PRESS RELEASE
US FDA approves Regeneron`s ultra-rare blood disease drug
19 Aug 2023 //
REUTERS
Rare rheumatology disease in spotlight after Sanofi, Regeneron nab first drug approval
05 Apr 2023 //
ENDPTS
Regeneron slams the brakes on rare disease trial following patient deaths
02 Nov 2020 //
ENDPTS
Regeneron therapy halves LDL cholesterol levels in rare genetic condition
15 Aug 2019 //
PHARMAFILE
NEJM publishes positive detailed results from Praluent® (alirocumab) CV trial
07 Nov 2018 //
GLOBENEWSWIRE
Sanofi, Regeneron skin cancer drug gets FDA nod
29 Sep 2018 //
REUTERS
Regeneron Gains on Eylea, Dupixent and Pipeline Progress
19 Sep 2018 //
NASDAQ
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.